{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:34:09Z","timestamp":1792524849155,"version":"4.5.0"},"publisher-location":"Chichester, UK","reference-count":71,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd006569.pub3","type":"reference-entry","created":{"date-parts":[[2009,10,21]],"date-time":"2009-10-21T18:36:53Z","timestamp":1256150213000},"source":"Crossref","is-referenced-by-count":48,"title":["Aripiprazole versus other atypical antipsychotics for schizophrenia"],"prefix":"10.1002","author":[{"given":"Katja","family":"Komossa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Rummel-Kluge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Hunger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany George G","family":"El-Sayeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Kissling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,10,7]]},"reference":[{"key":"10.1002\/14651858.CD006569.pub3-BIB1|cit1","unstructured":"BMS A multicenter, double-blind, randomized, comparative study of aripiprazole and olanzapine in the treatment of patients with acute schizophrenia Clinical Study Report CN138003 2005"},{"issue":"1","key":"10.1002\/14651858.CD006569.pub3-BIB2|cit2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4088\/JCP.v68n0104","article-title":"Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in chinese patients with risperidone as an active control: A randomized trial","volume":"68","author":"Chan","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006569.pub3-BIB3|cit3","first-page":"S497","article-title":"Aripiprazole versus risperidone in the treatment of acutely relapsed patients with schizophrenia in Taiwan: a randomized controlled trial","volume":"14","author":"Hwang","year":"2005","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"Suppl 18","key":"10.1002\/14651858.CD006569.pub3-BIB4|cit4","first-page":"47","article-title":"A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study","volume":"65","author":"McQuade","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006569.pub3-BIB5|cit5","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S0920-9964(03)80511-X","article-title":"Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder","volume":"60","author":"Potkin","year":"2003","journal-title":"Schizophrenia Research"},{"issue":"7","key":"10.1002\/14651858.CD006569.pub3-BIB6|cit6","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","article-title":"Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder","volume":"60","author":"Potkin","year":"2003","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD006569.pub3-BIB7|cit7","series-title":"Proceedings of the XIII World Congress of Psychiatry; 2005 10-15th Sept; Cairo, Egypt","article-title":"Naturalistic study of aripiprazole treatment","author":"Beuzen","year":"2005"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006569.pub3-BIB8|cit8","doi-asserted-by":"crossref","first-page":"S275","DOI":"10.1016\/S0924-977X(04)80317-1","article-title":"The risk of new-onset type 2 diabetes and coronary heart disease in chronic schizophrenic patients treated with aripiprazole and olanzapine","volume":"14","author":"Blonde","year":"2004","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006569.pub3-BIB9|cit9","series-title":"Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA","article-title":"Metabolic syndrome comparison between olanzapine, aripiprazole, and placebo","author":"Casey","year":"2003"},{"key":"10.1002\/14651858.CD006569.pub3-BIB10|cit10","first-page":"845","article-title":"A multicentre, randomised and double-blind controlled trial of aripiprazole in treatment of schizophrenia","volume":"11","author":"Chen","year":"2005","journal-title":"Chinese Journal of New Drugs and Clinical Remedies"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD006569.pub3-BIB11|cit11","first-page":"27","article-title":"Neurocognitive effects of aripiprazole versus olanzapine in patients with stable psychosis","volume":"53","author":"Cornblatt","year":"2002","journal-title":"Schizophrenia Research"},{"issue":"8","key":"10.1002\/14651858.CD006569.pub3-BIB12|cit12","first-page":"712","article-title":"Comparison of efficacy and safety of aripiprazole and quetiapine in the treatment of schizophrenia","volume":"14","author":"Dai","year":"2005","journal-title":"Chinese Journal of Behavioral Medical Science"},{"issue":"4","key":"10.1002\/14651858.CD006569.pub3-BIB13|cit13","first-page":"377","article-title":"Efficacy analysis of aripiprazole and clozapine in the treatment of schizophrenia","volume":"20","author":"Fan","year":"2005","journal-title":"Journal of North Sichuan Medical College"},{"issue":"10","key":"10.1002\/14651858.CD006569.pub3-BIB14|cit14","first-page":"853","article-title":"A controlled study of schizophrenia treated with aripiprazole and clozapine","volume":"11","author":"Han","year":"2005","journal-title":"Clinical Journal of Rehabilitation in Theory and Practice"},{"issue":"3","key":"10.1002\/14651858.CD006569.pub3-BIB15|cit15","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s00213-006-0428-x","article-title":"The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine","volume":"187","author":"Kern","year":"2006","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006569.pub3-BIB16|cit16","first-page":"184","article-title":"Comparative study on the effect of aripiprazole and risperidone on schizophrenia","volume":"20","author":"Mai","year":"2005","journal-title":"Chinese Journal of Rehabilitation"},{"issue":"4","key":"10.1002\/14651858.CD006569.pub3-BIB17|cit17","doi-asserted-by":"crossref","first-page":"S326","DOI":"10.1016\/S0924-977X(03)92058-X","article-title":"Efficacy and safety of aripiprazole versus perphenazine in treatment-resistant schizophrenia","volume":"13","author":"McQuade","year":"2003","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006569.pub3-BIB18|cit18","series-title":"Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada","article-title":"Improvement of non-hdl cholesterol levels among patients randomized to aripiprazole versus olanzapine","author":"Newcomer","year":"2006"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006569.pub3-BIB19|cit19","doi-asserted-by":"crossref","first-page":"S279","DOI":"10.1016\/S0924-977X(04)80327-4","article-title":"An economic evaluation of aripiprazole compared to olanzapine based on metabolic side-effect profile","volume":"14","author":"Ray","year":"2004","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006569.pub3-BIB20|cit20","series-title":"Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland","article-title":"Aripiprazole vs olanzapine in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week open-label extension study","author":"Sanchez","year":"2006"},{"key":"10.1002\/14651858.CD006569.pub3-BIB21|cit21","series-title":"Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada","article-title":"Effectiveness of atypical antipsychotics for substance abuse in schizophrenia patients","author":"Swanson","year":"2006"},{"issue":"1","key":"10.1002\/14651858.CD006569.pub3-BIB22|cit22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.schres.2005.12.857","article-title":"A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA)","volume":"84","author":"Tandon","year":"2006","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1002\/14651858.CD006569.pub3-BIB23|cit23","first-page":"301","article-title":"A controlled study of aripiprazole vs clozapine in the treatment of first-episode schizophrenia.","volume":"11","author":"Wang","year":"2005","journal-title":"Journal of Clinical Psychosomatic."},{"key":"10.1002\/14651858.CD006569.pub3-BIB24|cit24","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00213-006-0564-3","article-title":"Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine","volume":"189","author":"Chrzanowski","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD006569.pub3-BIB25|cit25","first-page":"616","article-title":"A comparative study between aripiprazole and risperidone in treatment of first-onset schizophrenia","volume":"6","author":"Ye","year":"2005","journal-title":"Wutaishan Hospital in Yangzhou City"},{"issue":"21","key":"10.1002\/14651858.CD006569.pub3-BIB26|cit26","first-page":"2787","article-title":"Comparison study of aripiprazole and risperidone on schizophrenia","volume":"14","author":"Zhi","year":"2005","journal-title":"Modern Journal of Integrated Traditional Chinese and Western Medicine"},{"key":"10.1002\/14651858.CD006569.pub3-BIB27|cit27","first-page":"1194","article-title":"Clinical study of therapeutic effects of aripiprazole in treatment of patients with schizophrenia","volume":"10","author":"Zhu","year":"2005","journal-title":"China"},{"key":"10.1002\/14651858.CD006569.pub3-BIB28|cit28","unstructured":"Eli Lilly Company Study of olanzapine vs aripiprazole in the treatment of schizophrenia Eli Lilly and Company Clinical Trial Registry 2003"},{"key":"10.1002\/14651858.CD006569.pub3-BIB29|cit29","unstructured":"Eli Lilly Company Olanzapine versus aripiprazole in the treatment of acutely ill patients with schizophrenia Eli Lilly and Company Clinical Trial Registry 2004"},{"key":"10.1002\/14651858.CD006569.pub3-BIB30|cit30","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006569.pub3-BIB31|cit31","unstructured":"American Psychiatric Association Practice guidelines for the treatment of patients with schizophrenia American Journal of Psychiatry 2004 1 114"},{"key":"10.1002\/14651858.CD006569.pub3-BIB32|cit32","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0893-133X(97)00112-7","article-title":"Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence","volume":"18","author":"Arnt","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006569.pub3-BIB33|cit33","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia.","volume":"154","author":"Barnes","year":"1989","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006569.pub3-BIB34|cit34","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD006569.pub3-BIB35|cit35","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD006569.pub3-BIB36|cit36","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"330","author":"Carpenter","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006569.pub3-BIB37|cit37","series-title":"Proceeding of the 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa","article-title":"Issues in the selection for meta-analyses of binary data","author":"Deeks","year":"2000"},{"key":"10.1002\/14651858.CD006569.pub3-BIB38|cit38","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD006569.pub3-BIB39|cit39","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006569.pub3-BIB40|cit40","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001359.pub2","article-title":"Olanzapine for schizophrenia","author":"Duggan","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006569.pub3-BIB41|cit41","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"13","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD006569.pub3-BIB42|cit42","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD006569.pub3-BIB43|cit43","unstructured":"U.S. Federal Drug Administration CDER Abilify (aripiprazole) tablets, medical review www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002"},{"key":"10.1002\/14651858.CD006569.pub3-BIB44|cit44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD006569.pub3-BIB45|cit45","unstructured":"Gaebel W Falkai P Weinmann S Wobrock T Treatment guidelines for schizophrenia Steinkopf 2006"},{"key":"10.1002\/14651858.CD006569.pub3-BIB46|cit46","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD006569.pub3-BIB47|cit47","article-title":"ECDEU assessment manual for psychopharmacology.","volume-title":"ECDEU assessment manual for psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD006569.pub3-BIB48|cit48","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1176\/appi.ajp.163.2.185","article-title":"Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine","volume":"163","author":"Heres","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006569.pub3-BIB49|cit49","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008] The Cochrane Collaboration 2008","DOI":"10.1002\/9780470712184"},{"key":"10.1002\/14651858.CD006569.pub3-BIB50|cit50","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of the effect on quality of life","volume":"63","author":"Jones","year":"2006","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD006569.pub3-BIB51|cit51","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment of treatment-resistant schizophrenia: a double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD006569.pub3-BIB52|cit52","first-page":"585","article-title":"Treatment programme and long term outcome in chronic schizophrenia","volume":"46","author":"Kane","year":"1993","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD006569.pub3-BIB53|cit53","volume-title":"Positive and negative syndrome scale (PANSS) manual","author":"Kay","year":"1986"},{"key":"10.1002\/14651858.CD006569.pub3-BIB54|cit54","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale Scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006569.pub3-BIB55|cit55","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1002\/14651858.CD006569.pub3-BIB56|cit56","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht","year":"2009","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006569.pub3-BIB57|cit57","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Liebermann","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006569.pub3-BIB58|cit58","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006569.pub3-BIB59|cit59","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00127-004-0762-4","article-title":"Schizophrenia and employment - a review.","volume":"39","author":"Marvaha","year":"2004","journal-title":"Social Psychiatry and Psychiatric Epidemiology"},{"key":"10.1002\/14651858.CD006569.pub3-BIB60|cit60","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT Statement: Revised Recommendations for Improving the Quality of Reports of Parallel- Group Randomized Trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD006569.pub3-BIB61|cit61","first-page":"329","article-title":"New assessment of atypical antipsychotics","volume":"71","author":"M\u00f6ller","year":"2000","journal-title":"Nervenarzt"},{"key":"10.1002\/14651858.CD006569.pub3-BIB62|cit62","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"issue":"1","key":"10.1002\/14651858.CD006569.pub3-BIB63|cit63","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1037\/0735-7028.34.1.108","article-title":"Aripiprazole: A novel antipsychotic with dopamine stabilising properties","volume":"34","author":"Rivas-Vasquez","year":"2003","journal-title":"Professional Psychology: Research and Practice"},{"key":"10.1002\/14651858.CD006569.pub3-BIB64|cit64","volume-title":"Modern Psychometrics","author":"Rust","year":"1989"},{"key":"10.1002\/14651858.CD006569.pub3-BIB65|cit65","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side-effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"key":"10.1002\/14651858.CD006569.pub3-BIB66|cit66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2008.04.011","article-title":"Schizophrenia, \"Just the Facts\" What we know in 2008. 2. Epidemiology and etiology","volume":"102","author":"Tandon","year":"2008","journal-title":"Schizophrenia research"},{"key":"10.1002\/14651858.CD006569.pub3-BIB67|cit67","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/archpsyc.1978.01770260031002","article-title":"Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality","volume":"35","author":"Tsuang","year":"1978","journal-title":"Archives of General Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD006569.pub3-BIB68|cit68","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD006569.pub3-BIB69|cit69","volume-title":"The World Health Report 2001 - Mental Health: New Understanding, New Hope","author":"WHO","year":"2001"},{"key":"10.1002\/14651858.CD006569.pub3-BIB70|cit70","series-title":"Proceedings of the 15th Cochrane Colloquium, Sao Paulo, 23-27 October 2007","article-title":"The Leeds Outcomes Stakeholders Survey (LOSS) Study","author":"Xia","year":"2007"},{"issue":"2","key":"10.1002\/14651858.CD006569.pub3-BIB71|cit71","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004578.pub3","article-title":"Aripiprazole for schizophrenia","author":"El-Sayeh","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD006569.pub3\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:01:13Z","timestamp":1628546473000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD006569.pub3"}},"subtitle":[],"editor":[{"given":"Katja","family":"Komossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2009,10,7]]},"references-count":71,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006569.pub3","relation":{},"subject":[],"published":{"date-parts":[[2009,10,7]]}}}